Aibo Bio focuses on mRNA vaccine research and development, molecular design, delivery system and other technical fields. In June, 2020, novel coronavirus mRNA vaccine (ARCoV) jointly developed by ABO Bio, Institute of Military Medicine, Academy of Military Sciences and watson biological, Yunnan officially passed the approval of drug clinical trials by the State Pharmaceutical Administration, and entered the first phase of clinical research, becoming the first mRNA vaccine in China. The vaccine can be stored at 2℃~8℃ for at least 6 months or at room temperature for 7 days.

In the past six months, Aibo Bio has completed a total of 750 million yuan of financing, namely, a round of financing of 2020110.5 billion yuan and a round of financing of 600 million yuan in April this year. Employers include Gaochun Venture Capital and Taifu Capital.